FDA Advises: Avastin No Good for Breast Cancer

A U.S. Food and Drug Administration advisory committee today unanimously recommended that Avastin should no longer be used to treat breast cancer, saying that the risks of the drug far outweighed any benefits. The recommendation was made after a two-day hearing that pitted the agency's Center for Drug Evaluation and Research against Genentech, Avastin's manufacturer. "Even though we have anecdotal information, we don't have evidence that it prolongs survival or improves quality of life,"...Full Story
Commenting on this article is closed.